Clinical Evaluation of Imipenem/Cilastatin Sodium and Fosfomycin as Second-Line Combination Chemotherapy in Severe Infections Associated with Hematologic Disorders

Shoichiro Tsuda, Yuko Kuzuyama, Hiroyuki Nakai, Taku Seriu, Teruyuki Takashima, Sinji Tanaka, Shigeo Horiike, Masafumi Taniwaki, Shinichi Misawa, Kei Kashima, Hitoshi Nakagawa, Hiroshi Fujii, Tetsuro Nakai, Yasuo Okawara, Hitosi Imanishi, Shohei Yokota, Hikari Nishigaki, Kazuhiro Nishida

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Imipenem/cilastatin sodium (IPM/CS) which is a broad-spectrum agent against both Gram-positive and -negative bacteria was used in combination with fosfomycin (FOM) as a second-line chemotherapy for severe infections associated with hematologic disorders. FOM was partnered with IPM because FOM may enhance the bacteriocidal effects of IPM when given as pretreatment to IPM/CS therapy.

Original languageEnglish (US)
Pages (from-to)171-183
Number of pages13
JournalJapanese Journal of Antibiotics
Volume46
Issue number2
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

Cilastatin
Fosfomycin
Combination Drug Therapy
Infection
Gram-Positive Bacteria
Gram-Negative Bacteria
Drug Therapy
imipenem drug combination cilastatin
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)
  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Clinical Evaluation of Imipenem/Cilastatin Sodium and Fosfomycin as Second-Line Combination Chemotherapy in Severe Infections Associated with Hematologic Disorders. / Tsuda, Shoichiro; Kuzuyama, Yuko; Nakai, Hiroyuki; Seriu, Taku; Takashima, Teruyuki; Tanaka, Sinji; Horiike, Shigeo; Taniwaki, Masafumi; Misawa, Shinichi; Kashima, Kei; Nakagawa, Hitoshi; Fujii, Hiroshi; Nakai, Tetsuro; Okawara, Yasuo; Imanishi, Hitosi; Yokota, Shohei; Nishigaki, Hikari; Nishida, Kazuhiro.

In: Japanese Journal of Antibiotics, Vol. 46, No. 2, 1993, p. 171-183.

Research output: Contribution to journalArticle

Tsuda, S, Kuzuyama, Y, Nakai, H, Seriu, T, Takashima, T, Tanaka, S, Horiike, S, Taniwaki, M, Misawa, S, Kashima, K, Nakagawa, H, Fujii, H, Nakai, T, Okawara, Y, Imanishi, H, Yokota, S, Nishigaki, H & Nishida, K 1993, 'Clinical Evaluation of Imipenem/Cilastatin Sodium and Fosfomycin as Second-Line Combination Chemotherapy in Severe Infections Associated with Hematologic Disorders', Japanese Journal of Antibiotics, vol. 46, no. 2, pp. 171-183. https://doi.org/10.11553/antibiotics1968b.46.171
Tsuda, Shoichiro ; Kuzuyama, Yuko ; Nakai, Hiroyuki ; Seriu, Taku ; Takashima, Teruyuki ; Tanaka, Sinji ; Horiike, Shigeo ; Taniwaki, Masafumi ; Misawa, Shinichi ; Kashima, Kei ; Nakagawa, Hitoshi ; Fujii, Hiroshi ; Nakai, Tetsuro ; Okawara, Yasuo ; Imanishi, Hitosi ; Yokota, Shohei ; Nishigaki, Hikari ; Nishida, Kazuhiro. / Clinical Evaluation of Imipenem/Cilastatin Sodium and Fosfomycin as Second-Line Combination Chemotherapy in Severe Infections Associated with Hematologic Disorders. In: Japanese Journal of Antibiotics. 1993 ; Vol. 46, No. 2. pp. 171-183.
@article{9f342c748a244e4a95b037ca2ea73bc6,
title = "Clinical Evaluation of Imipenem/Cilastatin Sodium and Fosfomycin as Second-Line Combination Chemotherapy in Severe Infections Associated with Hematologic Disorders",
abstract = "Imipenem/cilastatin sodium (IPM/CS) which is a broad-spectrum agent against both Gram-positive and -negative bacteria was used in combination with fosfomycin (FOM) as a second-line chemotherapy for severe infections associated with hematologic disorders. FOM was partnered with IPM because FOM may enhance the bacteriocidal effects of IPM when given as pretreatment to IPM/CS therapy.",
author = "Shoichiro Tsuda and Yuko Kuzuyama and Hiroyuki Nakai and Taku Seriu and Teruyuki Takashima and Sinji Tanaka and Shigeo Horiike and Masafumi Taniwaki and Shinichi Misawa and Kei Kashima and Hitoshi Nakagawa and Hiroshi Fujii and Tetsuro Nakai and Yasuo Okawara and Hitosi Imanishi and Shohei Yokota and Hikari Nishigaki and Kazuhiro Nishida",
year = "1993",
doi = "10.11553/antibiotics1968b.46.171",
language = "English (US)",
volume = "46",
pages = "171--183",
journal = "The Journal of antibiotics. Ser. B",
issn = "0368-2781",
publisher = "Japan Antibiotics Research Association",
number = "2",

}

TY - JOUR

T1 - Clinical Evaluation of Imipenem/Cilastatin Sodium and Fosfomycin as Second-Line Combination Chemotherapy in Severe Infections Associated with Hematologic Disorders

AU - Tsuda, Shoichiro

AU - Kuzuyama, Yuko

AU - Nakai, Hiroyuki

AU - Seriu, Taku

AU - Takashima, Teruyuki

AU - Tanaka, Sinji

AU - Horiike, Shigeo

AU - Taniwaki, Masafumi

AU - Misawa, Shinichi

AU - Kashima, Kei

AU - Nakagawa, Hitoshi

AU - Fujii, Hiroshi

AU - Nakai, Tetsuro

AU - Okawara, Yasuo

AU - Imanishi, Hitosi

AU - Yokota, Shohei

AU - Nishigaki, Hikari

AU - Nishida, Kazuhiro

PY - 1993

Y1 - 1993

N2 - Imipenem/cilastatin sodium (IPM/CS) which is a broad-spectrum agent against both Gram-positive and -negative bacteria was used in combination with fosfomycin (FOM) as a second-line chemotherapy for severe infections associated with hematologic disorders. FOM was partnered with IPM because FOM may enhance the bacteriocidal effects of IPM when given as pretreatment to IPM/CS therapy.

AB - Imipenem/cilastatin sodium (IPM/CS) which is a broad-spectrum agent against both Gram-positive and -negative bacteria was used in combination with fosfomycin (FOM) as a second-line chemotherapy for severe infections associated with hematologic disorders. FOM was partnered with IPM because FOM may enhance the bacteriocidal effects of IPM when given as pretreatment to IPM/CS therapy.

UR - http://www.scopus.com/inward/record.url?scp=0027414510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027414510&partnerID=8YFLogxK

U2 - 10.11553/antibiotics1968b.46.171

DO - 10.11553/antibiotics1968b.46.171

M3 - Article

C2 - 8331778

AN - SCOPUS:0027414510

VL - 46

SP - 171

EP - 183

JO - The Journal of antibiotics. Ser. B

JF - The Journal of antibiotics. Ser. B

SN - 0368-2781

IS - 2

ER -